Evolus (EOLS) Announces Proposed Public Offering of Common Stock

Evolus, Inc. (Nasdaq: EOLS) (“Evolus”) announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. Evolus expects to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares in the offering are to be sold by Evolus.

Evolus intends to use the net proceeds of the offering to continue to fund the commercialization of Jeuveau®, and the remainder for working capital, research and development and general corporate purposes.

SVB Leerink, Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. are acting as joint bookrunning managers for the offering.

You May Also Be Interested In

• Definium Therapeutics plans $500M public share offering
• RedHill Biopharma closes $6M private placement with warrant upside
• ITG launches IPO roadshow, seeks Nasdaq listing at up to $22 per share